Commentaries, Letters, etc

Altman DG. Systematic reviewers face challenges from varied study designs. [commentary] BMJ 2002; 325: 464.

Altman DG, Bland JM. Commentary on quantifying agreement between two methods of measurement. [commentary] Clin Chem 2002; 48: 801-802.

Altman DG, Moher D, Schulz KF. Peer review of statistics in medical research. Reporting power calculations is important. [letter] BMJ 2002; 325: 492.

Altman DG, Schulz KF, Moher D. CONSORT statement requires closer examination. [letter] BMJ 2002; 325: 1364.

Altman DG, Schulz KF, Moher D. Results of randomised trials relative or absolute effect measures? [letter] BMJ (4 September 2002)

Deeks JJ. On eradicating publication bias, and the realities of independent reviews. [letter] BMJ (14 November 2002).

Diggle L, Deeks JJ. The position statement on injection technique. [letter] Arch Dis Child 2002; 87: 452-453.

Egger M, Altman DG, Schulz KF. The revised CONSORT Statement: explanation and elaboration. [authors response] Ann Intern Med 2002; 136: 926-927.

Jenkinson ML, Deeks JJ. On presentation and analysis. [letter] BMJ (30 October 2002).

Moayyedi P, Deeks J, Forman D. Helicobacter pylori eradication therapy for nonulcer dyspepsia. [letter] Ann Intern Med 2002; 136: 555-556.

Moher D, Altman DG, Schulz KF. Reporting the clinical importance of randomized controlled trials. [letter] Can Med Assoc J 2002; 166: 711-712.

Moher D, Schulz KF, Altman DG, Rennie D. Reflections on medical journals. [letter] Ann Intern Med 2002; 137: 1011-1012.

Parmar MKB, Spiegelhalter DJ, Griffiths GO, Altman DG, Souhami RL. Bayesian stopping rules for trials. [authors reply] Lancet 2002; 359: 76-77.

Schulz KF, Altman DG, Moher D. Allocation concealment in clinical trials. [letter] JAMA 2002; 288: 2406-2407.

Schulz KF, Moher D, Altman DG. Interpreting the number needed to treat. [letter] JAMA 2002; 288: 831.

Whitlock G, Clark TG. The effect of missing values for covariates. [letter] Epidemiology 2002; 13: 113.